ATP13A2 and Parkinson disease: Supporting this therapeutic possibility was the finding that surviving nigral dopamine neurons in patients with sporadic PD express ATP13A2 mRNA at 5 to 10-fold higher levels than controls [1], although ATP13A2 protein levels show a more modest increase in these neurons [4].